Skip to content
CAPRCapricor Therapeutics, Inc.

Earnings

When Capricor Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

66 quarters. Jun 30, 2010 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 11, after the close

Thu, Mar 11, 2027in 114 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 9 – 31

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2024 −7.9%, Q3 2024 −63.4%, Q2 2024 +1.4%, Q1 2024 +64.3%
Net income
-$30.17M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2024 · derived$11.13M−7.9% vs Q4 2023

Latest results

  1. Q3 2026Nov 10, 2026, after the closeThe release+26.5%by the close of Nov 11
    Revenue
    —
    —
    Net income
    -$42.66M
    N/M
    EPS
    -$0.73
    N/M
    Read · nothing to show
  2. Q2 2026Aug 13, 2026, after the closeThe release+58.0%by the close of Aug 14
    Revenue
    —
    —
    Net income
    -$40.73M
    N/M
    EPS
    -$0.70
    N/M
  3. Q1 2026May 12, 2026, after the closeThe release3.5%by the close of May 13
    Revenue
    —
    —
    Net income
    -$33.94M
    N/M
    EPS
    -$0.59
    N/M
  4. Q4 2025Mar 12, 2026, after the closeThe release8.6%by the close of Mar 13
    Revenue
    —
    —
    Net income
    -$30.17M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 10, 2026 · after-hoursNov 10, 202641 d10-Q——-$0.73+26.5%
Q2 2026Jun 30, 2026Aug 13, 2026 · after-hoursAug 14, 202645 d10-Q——-$0.70+58.0%
Q1 2026Mar 31, 2026May 12, 2026 · after-hoursMay 13, 202643 d10-Q——-$0.593.5%
FY 2025
Q4 2025derivedDec 31, 2025Mar 12, 2026 · after-hoursMar 17, 202676 d10-K———8.6%
Q3 2025Sep 30, 2025Nov 10, 2025 · after-hoursNov 10, 202541 d10-Q——-$0.54+11.1%
Q2 2025Jun 30, 2025Aug 11, 2025 · after-hoursAug 11, 202542 d10-Q——-$0.57+2.8%
Q1 2025Mar 31, 2025May 13, 2025 · after-hoursMay 14, 202544 d10-Q——-$0.53+5.1%
FY 2024
Q4 2024derivedDec 31, 2024Mar 19, 2025 · after-hoursMar 26, 202585 d10-K$11.13M−7.9%—+17.6%
Q3 2024Sep 30, 2024Nov 13, 2024 · after-hoursNov 14, 202445 d10-Q$2.26M−63.4%-$0.38+9.3%
Q2 2024Jun 30, 2024Aug 7, 2024 · after-hoursAug 8, 202439 d10-Q$3.97M+1.4%-$0.35+9.0%
Q1 2024Mar 31, 2024May 13, 2024 · after-hoursMay 14, 202444 d10-Q$4.91M+64.3%-$0.31—
Earlier years, FY 2010 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 10, 2026125355
10-QAug 14, 2026097294
10-QMay 13, 2026060382
10-KMar 17, 2026029580
10-QNov 10, 2025109298
10-QAug 11, 2025011084
10-QMay 14, 2025007770
10-KMar 26, 2025003707
10-QNov 14, 2024015730
10-QAug 8, 2024011638

Provenance

ProvenanceData status and checks

Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR